Abstract:Vascular endothelial growth factor receptor 3(VEGFR-3),a specific receptor of vascular endothelial growth factor C(VEGF-C),is a new member of tyrosine kinase receptor family.VEGFR-3 is consisted of extracellular,transmembrane and intracellular regions.The extracellular region comprises of seven immunoglobin-like domains,among which the first three domains(1-3Ig) play especially important roles in VEGF-C/VEGFR-3 signaling pathway,because these domains are responsible for the binding between VEGFR-3 and VEGF-C.Lymphatic endothelial progenitor cells(LEPCs) are mainly localized to the bone marrow,but can be released from bone marrow into diseased tissues in case of inflammation,ischemia or tumour,etc,and differentiated into lymphatic endothelial cells(LEC) to participate in the lymphangiogenesis in tumour tissues.As VEGF-C/VEGFR-3 signaling pathway is critical for the differentiation of LEPCs into LEC in tumour tissue,blockage of this signaling pathway will therefore be useful for inhibiting lymphangiogenesis and for the anti-tumour treatment.It is suggested that soluble VEGFR-3 can interfere with the binding between the VEGF-C and membrane-bound VEGFR-3,and thus can block VEGF-C/VEGFR-3 signaling pathway.In this study,we investigate the secretion of soluble VEGFR-3 proteins in LEPCs after transfected with recombinant adenovirus containing VEGFR-3(1-3Ig) gene of BABL/c mouse and the biological activity of the secreted protein.The gene encoding VEGFR-3(1-3Ig) was obtained through nested RT-PCR from BABL/c mouse placenta,and human CD33 signal peptide was added to the N-terminal of the PCR product through recombinant PCR technique.Then the gene fragment was cloned into the adenovirus shuttle plasmid pDC316-IRES-EGFP.After confirmed by restriction enzyme digestion and DNA sequencing,the recombinant adenovirus vector carrying VEGFR-3(1-3Ig) was transfected into 293-cells together with the packing vector to produce the recombinant adenovirus.The recombinant adenovirus was used to transfect LEPCs,and ELISA was employed to quantify the amount of soluble VEGFR-3 protein in the culture medium from transfected LEPCs.The biological activity of the soluble VEGFR-3 was determined by its ability to neutralize VEGF-C.Results showed that an adenovirus expression vector for soluble VEGFR-3 was successfully constructed,which can produce high titer recombinant adenovirus containing VEGFR-3(1-3Ig) of BABL/c mouse in 293-cells after transfection with packing vector.On transfection with the recombinant adenovirus carrying VEGFR-3(1-3Ig),LEPCs can release soluble VEGFR-3 as determined by ELISA,and the released VEGFR-3 can neutralize VEGFC efficiently.In conlusion,we demonstrated that LEPCs can express and secrete soluble VEGFR-3 protein after transfected with recombinant adenovirus containing BABL/c mouse VEGFR-3(1-3Ig) gene,and the released soluble VEGFR-3 protein to neutralize VEGF-C.This study has laid a foundation for the application of VEGFR-3 gene-transfected LEPCs in the antitumor treatment.

VEGFR-3 Gene Transfection for Its Soluble VEGFR-3 Release in Lymphatic Endothelial Progenitor Cells

Directing Endothelial Differentiation of Human Embryonic Stem Cells Via Transduction with an Adenoviral Vector Expressing the VEGF165 Gene

[Expression of Human VEGF165 Gene in Rat Bone Marrow Stromal Cells in Vitro].

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

Gene cloning of secreted VEGF receptor flt-1 (I similar to IV extracellular domain) and the corresponding recombinant adenovirus construction and expression

Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with Vegfr-3 Sirna Delivered with Pei-Alginate Nanoparticles

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

[Activation of Signal Transducers and Activators of Transcription Induced by Vascular Endothelial Growth Factor in CD34+ Hematopoietic Progenitor Cells in Vitro].

Expression of Human Vascular Endothelial Growth Factor in Cultured NIH3T3 Cells

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

[Preparation and characterization of Ad-ERα-36-Fc-GFP].

[Construction of Recombinant Adenovirus Vector of Calcitonin Gene-Related Peptide Gene and Transfection to Neonatal Rat Cardiomyocytes].

Cd34(+)Vegfr-3(+) Progenitor Cells Have A Potential to Differentiate Towards Lymphatic Endothelial Cells

Generation of Scfv Specific to Human Vegfr-3 from the Neutralizing Mab Bdd073

Construction and Function Identification of Recombinant Mouse Soluble Endoglin and Soluble Fms-Like Tyrosine Kinase-1 Mediated by Adenovirus

Cellular Repressor of E1A-stimulated Gene on Endothelial Cell Angiogenesis Via ILK/VEGF Pathway

THE EFFECTS OF CYTOKINES ON THE MIGRATION AND MOBILIZATION OF LYMPHATIC ENDOTHELIAL PROGENITOR CELLS

[Expression of VEGF165 and VEGF121 Genes in MC3T3-E1 Cell Line and Biological Function of Their Products].

EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 IN HUMAN BREAST CANCER AND ITS SIGNIFICANCE